GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+46.03%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$352M
AUM Growth
+$352M
(+73%)
Cap. Flow
+$96.4M
Cap. Flow
% of AUM
27.4%
Top 10 Holdings %
Top 10 Hldgs %
53.9%
Holding
48
New
11
Increased
10
Reduced
8
Closed
9
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$30.6M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$20.8M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$19.2M |
| 4 |
SAGE
Sage Therapeutics
SAGE
|
$11.4M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$10.7M |
Top Sells
Sector Composition
| 1 | Healthcare | 91.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $45.3M | 11.84% | 385,000 +260,000 | +208% | +$30.6M |
|
|
2
Acadia Pharmaceuticals
ACAD
$4.38B
| $24.2M | 6.31% | 900,000 +775,000 | +620% | +$20.8M |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $19.2M | 5.02% | +240,000 | New | +$19.2M |
|
4
Amicus Therapeutics
FOLD
$2.34B
| $17.7M | 4.62% | 1,300,000 +650,000 | +100% | +$8.84M |
|
|
GBT
5
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $15.9M | 4.15% | 300,000 +200,000 | +200% | +$10.6M |
|
|
IMMU
6
DELISTED
Immunomedics Inc
IMMU
| $15.4M | 4.02% | 800,000 | – | – |
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $14.7M | 3.84% | 80,000 | – | – |
|
|
8
Alnylam Pharmaceuticals
ALNY
$58.5B
| $14M | 3.66% | 150,000 +115,000 | +329% | +$10.7M |
|
|
SAGE
9
DELISTED
Sage Therapeutics
SAGE
| $11.9M | 3.12% | 75,000 +71,700 | +2,173% | +$11.4M |
|
10
KalVista Pharmaceuticals
KALV
$678M
| $11.4M | 2.99% | 400,000 -25,000 | -6% | -$716K |
|
11
Travere Therapeutics
TVTX
$1.56B
| $11.3M | 2.96% | 500,000 | – | – |
|
|
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $11M | 2.87% | 150,000 -250,000 | -63% | -$18.3M |
|
13
Iovance Biotherapeutics
IOVA
$807M
| $10.9M | 2.86% | 1,150,000 +150,000 | +15% | +$1.43M |
|
14
Rocket Pharmaceuticals
RCKT
$354M
| $10.5M | 2.75% | 600,000 | – | – |
|
|
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
| $9.96M | 2.6% | +750,000 | New | +$9.96M |
|
16
Protagonist Therapeutics
PTGX
$3.67B
| $8.8M | 2.3% | +700,000 | New | +$8.8M |
|
17
Invesco CurrencyShares Swiss Franc Trust
FXF
$376M
| $8.57M | 2.24% | 91,800 +36,600 | +66% | +$3.42M |
|
18
AnaptysBio
ANAB
$569M
| $8.4M | 2.19% | 115,000 -25,000 | -18% | -$1.83M |
|
|
MNTA
19
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $7.27M | 1.9% | 500,000 +175,000 | +54% | +$2.54M |
|
|
BOLD
20
DELISTED
Audentes Therapeutics, Inc
BOLD
| $6.83M | 1.78% | 175,000 -125,000 | -42% | -$4.88M |
|
|
RARX
21
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $6.72M | 1.76% | +300,000 | New | +$6.72M |
|
|
DBVT
22
DBV Technologies
DBVT
$264M
| $6.55M | 1.71% | +850,000 | New | +$6.55M |
|
|
EPZM
23
DELISTED
Epizyme, Inc
EPZM
| $6.2M | 1.62% | +500,000 | New | +$6.2M |
|
24
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $6.14M | 1.6% | +450,000 | New | +$6.14M |
|
|
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
| $5.79M | 1.51% | 150,000 -100,000 | -40% | -$3.86M |
|